VHL and renal cell carcinoma: The primary objective of the trial is to identify the maximum tolerated dose (MTD) of HC-7366 in combination with belzutifan for patients with locally advanced or metastatic RCC with predominantly clear cell histology, regardless of VHL gene mutation status.